IMVT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMVT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Immunovant's annualized ROCE % for the quarter that ended in Mar. 2024 was -49.88%.
The historical data trend for Immunovant's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant Annual Data | |||||||||||||||
Trend | Dec18 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||
ROCE % | Get a 7-Day Free Trial | -139.58 | -44.33 | -36.09 | -49.97 | -55.13 |
Immunovant Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -66.12 | -79.68 | -89.62 | -52.88 | -49.88 |
Immunovant's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Mar. 2024 ) | (A: Mar. 2023 ) | (A: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Mar. 2024 ) | (A: Mar. 2023 ) | (A: Mar. 2024 ) | |||||
= | -270.209 | / | ( ( (405.838 - 43.297) | + | (666.365 - 48.608) ) | / 2 ) | |
= | -270.209 | / | ( (362.541 | + | 617.757) | / 2 ) | |
= | -270.209 | / | 490.149 | ||||
= | -55.13 % |
Immunovant's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -323.516 | / | ( ( (711.446 - 32.102) | + | (666.365 - 48.608) ) | / 2 ) | |
= | -323.516 | / | ( ( 679.344 | + | 617.757 ) | / 2 ) | |
= | -323.516 | / | 648.5505 | ||||
= | -49.88 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant (NAS:IMVT) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Immunovant's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
William L. Macias | officer: Chief Medical Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Eva Renee Barnett | officer: Chief Financial Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Julia G. Butchko | officer: Chief Dev. & Tech. Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Peter Salzmann | director, officer: Chief Executive Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Andrew J. Fromkin | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139 |
George V Migausky | director | C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Mark S. Levine | officer: Chief Legal Officer | 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Jay S Stout | officer: Chief Technology Officer | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Frank Torti | director | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Douglas J. Hughes | director | C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134 |
Rita Jain | officer: Chief Medical Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Michael James Elliott | officer: Chief Scientific Officer | 320 WEST 37TH STREET, NEW YORK NY 10018 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-26-2022
By PRNewswire • 09-28-2023
By GlobeNewswire • 09-28-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By Marketwired • 09-26-2023
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By GuruFocus Research • 10-07-2023
By GlobeNewswire • 09-26-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.